Rani Therapeutics Holdings Inc reports a Return on Equity (ROE) of -103.65%.

What is RANI's dividend yield?

Rani Therapeutics Holdings Inc offers a dividend yield of 0.00%.

What is RANI's Quality Score?

Our AI rates RANI's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RANI?

Our AI Timing Score for RANI is 51 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RANI belong to?

Rani Therapeutics Holdings Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Rani Therapeutics Holdings Inc (RANI) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

RANI AI Analysis Summary

Our AI summary for RANI: Rani Therapeutics Holdings Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -103.65%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 51/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RANI

Rani Therapeutics Holdings Inc

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 0.82

0.02 (2.33%) Day Change

Watchlist Portfolio Compare Chart

0.05

D/E

-103.7%

ROE

-56.8%

ROA

0.00%

Div Yield

RANI THERAPEUTICS HOLDINGS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.82 Price 0.02 (2.33%) Day Change	NEWS SCORE: N/A

RANI, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	0.82
PBV / Sector	3.10 / 44,022.72
Earning Per Share	-0.22

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	0.83 M GREAT
Average 1W Daily Value	0.50 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-929.06 / 98.24
NPM Average (%) / Sector	-1,888.73 / -1,697.63
NPM Change Average (%) / Sector	N/A / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-56.75 / 185,260.96
ROA Average (%) / Sector	-55.26 / 36,684.70
ROA Change Average (%) / Sector	30.18 / 422,221.66 GREAT
ROE (%) / Sector	-103.65 / 243,762.23
ROE Average (%) / Sector	-409.50 / 48,758.47
ROE Change Average (%) / Sector	152.54 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:45
Symbol	RANI
Name	RANI THERAPEUTICS HOLDINGS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	112.39 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	110.17 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2051 Ringwood Avenue, San Jose, CA, United States, 95131

Phone: 408 457 3700

Website: https://www.ranitherapeutics.com

Employees: 69

Sector: Healthcare >> Biotechnology

Description: Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd. to expand obesity pipeline across multiple novel candidates. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.